Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
暂无分享,去创建一个
J. Kirkwood | H. Tawbi | S. Moschos | C. Sander | W. Gooding | Yongli Shuai | A. Tarhini | J. Cherian
[1] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[3] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[4] A. Ribas,et al. Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. , 2010 .
[5] D. Schadendorf,et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.
[6] J. Wetterö,et al. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares? , 2009, Arthritis and rheumatism.
[7] S. Chasalow,et al. Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[9] J. Kirkwood,et al. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers , 2008 .
[10] J. Kirkwood,et al. Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Wolchok,et al. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment , 2008 .
[12] G. Linette,et al. Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study , 2008 .
[13] A. Hauschild,et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma , 2008 .
[14] A. Hauschild,et al. A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma , 2008 .
[15] A. Hauschild,et al. Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma , 2008, Cancer.
[16] Donna Niedzwiecki,et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Kirkwood,et al. Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696 , 2007 .
[18] John M. Kirkwood,et al. Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-α2b , 2007, Clinical Cancer Research.
[19] D. Jukic,et al. Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b , 2007, Clinical Cancer Research.
[20] D. Jukic,et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Kirkwood,et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.
[22] B. Comin-Anduix,et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] L. Marnell,et al. C-reactive protein: ligands, receptors and role in inflammation. , 2005, Clinical immunology.
[24] S. Groshen,et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] B. Kahle,et al. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase , 2004, British Journal of Cancer.
[26] R. J. Mather,et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. , 2004 .
[27] D. Tough. Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation , 2004, Leukemia & lymphoma.
[28] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Sosman,et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. , 2002, Cancer.
[30] J. Kirkwood,et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] T. Di Pucchio,et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. , 2001, Blood.
[32] S. Steinberg,et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] B. Foster,et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.
[34] M. Gore,et al. Interferon‐alpha (IFN‐α) stimulates anti‐melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC) , 2000, Clinical and experimental immunology.
[35] B. Foster,et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Allison,et al. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.
[37] J. Bluestone,et al. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. , 1999, Journal of immunology.
[38] G. Brabant,et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] A. N. Park,et al. Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells , 1998, Journal of leukocyte biology.
[40] C. Thompson,et al. Brief Definitive Report Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28 , 2022 .
[41] M. Biffi,et al. Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells , 1997, The Journal of experimental medicine.
[42] K. Murphy,et al. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. , 1996, Journal of immunology.
[43] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[44] S. Steinberg,et al. Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin‐2 Alone , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[45] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[46] J. Allison,et al. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.
[47] J. Becker,et al. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma , 1994, Cancer.
[48] C. Heusser,et al. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells , 1993, The Journal of experimental medicine.
[49] J. Carballido,et al. Interferon‐alpha‐2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder , 1993, Cancer.
[50] N. Weijl,et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[52] M. Atkins,et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. , 1988, The New England journal of medicine.
[53] F. Denizot,et al. A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.
[54] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[55] J. Kirkwood,et al. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. , 2008, Expert opinion on biological therapy.
[56] T. Whiteside,et al. Interleukin-10 and Transforming Growth Factor-B1Mediates Suppression in the Tumor Microenvironment , 2007 .
[57] A. Ribas,et al. Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-Dioxygenase (IDO) Expression With the CTLA4 Blocking MAB CP-675,206 , 2006 .
[58] J. Kirkwood,et al. Patients With Renal Cell Carcinoma or Melanoma , 2002 .
[59] A. Ohta,et al. The critical role of Th1-dominant immunity in tumor immunology , 2000, Cancer Chemotherapy and Pharmacology.
[60] J. Bluestone,et al. CD28-Regulated Activation of Th2 Responses Knockout Mice Is Characterized by Lymphoproliferative Disorder in CTLA-4 , 1999 .
[61] S. Rosenberg,et al. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[62] P. Carlini,et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. , 1990, European journal of cancer.